Gresham House Ventures – a growth equity investor specialised in software and digitally driven businesses in the healthcare, consumer and services sectors – has invested £2.25m into Metrion Biosciences, a contract research organisation (CRO) catering to the drug discovery market.
Metrion Biosciences (Metrion) is a specialist contract research company providing drug discovery services to the worldwide pharmaceutical and biotechnology industry. The Company is a leader in the field of ion channel biology and works with life science companies to assess the activity of innovative new compounds on human ion channels associated with disease, as well as to screen potential new drugs for off-target effects.
Gresham House plc (LON:GHE) is a London Stock Exchange quoted specialist alternative asset manager offering funds, direct investment and tailored investment solutions, including co-investment, in public equity, private assets, forestry, new energy and housing.